Proteomics - Human Diseases and Protein Functions 2012
DOI: 10.5772/31776
|View full text |Cite
|
Sign up to set email alerts
|

Exploring the Role of Biomarkers for the Diagnosis and Management of Traumatic Brain Injury Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
5
2

Relationship

4
3

Authors

Journals

citations
Cited by 15 publications
(15 citation statements)
references
References 143 publications
0
15
0
Order By: Relevance
“…They include neuronal cell body injury marker Ubiquitin C-terminal hydrolase-L1 (UCH-L1), breakdown products of axonally enriched aII-spectrin (SBDP150 and SBDP145 produced by necrosis-linked calpain protease and SBDP120 produced by the apoptosis-linked caspase-3 protease), dendritic injury marker microtubule-associated protein-2 (MAP-2), glial marker S100b and demyelination marker myelin basic protein (MBP) [37][38][39]. The table in the appendix describes the Lower (LLoD) and Upper (ULoD) limits of detection for each of the seven biomarkers.…”
Section: Biomarker Analysismentioning
confidence: 99%
“…They include neuronal cell body injury marker Ubiquitin C-terminal hydrolase-L1 (UCH-L1), breakdown products of axonally enriched aII-spectrin (SBDP150 and SBDP145 produced by necrosis-linked calpain protease and SBDP120 produced by the apoptosis-linked caspase-3 protease), dendritic injury marker microtubule-associated protein-2 (MAP-2), glial marker S100b and demyelination marker myelin basic protein (MBP) [37][38][39]. The table in the appendix describes the Lower (LLoD) and Upper (ULoD) limits of detection for each of the seven biomarkers.…”
Section: Biomarker Analysismentioning
confidence: 99%
“…There have been a number of biomarkers assessed for TBI [56, 57]. The most extensively studied among these include glial protein S-100 beta (β) [5860], neuron-specific enolase (NSE) [6164], and myelin basic protein (MBP) [6567].…”
Section: Future Researchmentioning
confidence: 99%
“…13 Important properties that should be considered when evaluating a biomarker for clinical application include: 1) demonstrate a high sensitivity and specificity for brain injury, 2) stratify patients by severity of injury, 3) have a rapid appearance in accessible biological fluid, 4) provide information about injury mechanisms, 5) have well-defined biokinetc properties, 6) monitor progress of disease and response to treatment, and 7) predict functional outcome. 13,14 …”
Section: Introductionmentioning
confidence: 99%